VDR and chronic kidney disease: In the last decade, one of the most relevant therapeutic innovations in the field of CKD has been the introduction of paricalcitol (19-nor-1,25-dihydroxyvitamin D2), a selective activator of the vitamin D receptor for the prevention and treatment of secondary hyperparathyroidism [7, 8].